Fecal Microbiota Therapy with a Focus on C. difficile Infection

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

ABSTRACT: There has been a paradigm shift in our view of bacteria away from their role as just pathogens. We now have a deepening appreciation of their critical influences in our health maintenance, including energy harvest, metabolism, intestinal development, cell proliferation, nervous system and immune function, as well as their role to protect against intestinal and other infections. A perturbed intestinal microbiome has been associated with an increasing number of gastrointestinal (GI) and non-GI diseases but particularly with C. difficile infection (CDI). While such association does not imply causation, it has been shown that fecal microbiota transplantation (FMT) can correct the dysbiosis that characterizes chronic and recurring CDI, and that FMT can effect a seemingly safe and rapidly effective cure for the majority of CDI patients so treated. FMT has been used to treat a wide range of other diseases, although conclusions about efficacy in any disease other than CDI must await appropriate well-designed trials. More work needs to be done with FMT, especially to evaluate and ensure its long-term safety. Future studies are likely to narrow the spectrum of organisms that needs to be given to patients to cure CDI, and perhaps other diseases, and to elucidate the mechanisms whereby such therapeutic benefit occurs. FMT is but the first step in this journey.

Original languageEnglish (US)
JournalPsychosomatic Medicine
DOIs
StateAccepted/In press - Jul 7 2017

Fingerprint

Microbiota
Infection
Therapeutics
Dysbiosis
Causality
Energy Metabolism
Nervous System
Therapy
Cell Proliferation
Fecal Microbiota Transplantation
Transplantation
Bacteria
Safety
Health

ASJC Scopus subject areas

  • Developmental and Educational Psychology
  • Arts and Humanities (miscellaneous)
  • Applied Psychology
  • Psychiatry and Mental health

Cite this

Fecal Microbiota Therapy with a Focus on C. difficile Infection. / Brandt, Lawrence J.

In: Psychosomatic Medicine, 07.07.2017.

Research output: Contribution to journalArticle

@article{79a25a9c0eba44ff879fcaab823de2f4,
title = "Fecal Microbiota Therapy with a Focus on C. difficile Infection",
abstract = "ABSTRACT: There has been a paradigm shift in our view of bacteria away from their role as just pathogens. We now have a deepening appreciation of their critical influences in our health maintenance, including energy harvest, metabolism, intestinal development, cell proliferation, nervous system and immune function, as well as their role to protect against intestinal and other infections. A perturbed intestinal microbiome has been associated with an increasing number of gastrointestinal (GI) and non-GI diseases but particularly with C. difficile infection (CDI). While such association does not imply causation, it has been shown that fecal microbiota transplantation (FMT) can correct the dysbiosis that characterizes chronic and recurring CDI, and that FMT can effect a seemingly safe and rapidly effective cure for the majority of CDI patients so treated. FMT has been used to treat a wide range of other diseases, although conclusions about efficacy in any disease other than CDI must await appropriate well-designed trials. More work needs to be done with FMT, especially to evaluate and ensure its long-term safety. Future studies are likely to narrow the spectrum of organisms that needs to be given to patients to cure CDI, and perhaps other diseases, and to elucidate the mechanisms whereby such therapeutic benefit occurs. FMT is but the first step in this journey.",
author = "Brandt, {Lawrence J.}",
year = "2017",
month = "7",
day = "7",
doi = "10.1097/PSY.0000000000000511",
language = "English (US)",
journal = "Psychosomatic Medicine",
issn = "0033-3174",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Fecal Microbiota Therapy with a Focus on C. difficile Infection

AU - Brandt, Lawrence J.

PY - 2017/7/7

Y1 - 2017/7/7

N2 - ABSTRACT: There has been a paradigm shift in our view of bacteria away from their role as just pathogens. We now have a deepening appreciation of their critical influences in our health maintenance, including energy harvest, metabolism, intestinal development, cell proliferation, nervous system and immune function, as well as their role to protect against intestinal and other infections. A perturbed intestinal microbiome has been associated with an increasing number of gastrointestinal (GI) and non-GI diseases but particularly with C. difficile infection (CDI). While such association does not imply causation, it has been shown that fecal microbiota transplantation (FMT) can correct the dysbiosis that characterizes chronic and recurring CDI, and that FMT can effect a seemingly safe and rapidly effective cure for the majority of CDI patients so treated. FMT has been used to treat a wide range of other diseases, although conclusions about efficacy in any disease other than CDI must await appropriate well-designed trials. More work needs to be done with FMT, especially to evaluate and ensure its long-term safety. Future studies are likely to narrow the spectrum of organisms that needs to be given to patients to cure CDI, and perhaps other diseases, and to elucidate the mechanisms whereby such therapeutic benefit occurs. FMT is but the first step in this journey.

AB - ABSTRACT: There has been a paradigm shift in our view of bacteria away from their role as just pathogens. We now have a deepening appreciation of their critical influences in our health maintenance, including energy harvest, metabolism, intestinal development, cell proliferation, nervous system and immune function, as well as their role to protect against intestinal and other infections. A perturbed intestinal microbiome has been associated with an increasing number of gastrointestinal (GI) and non-GI diseases but particularly with C. difficile infection (CDI). While such association does not imply causation, it has been shown that fecal microbiota transplantation (FMT) can correct the dysbiosis that characterizes chronic and recurring CDI, and that FMT can effect a seemingly safe and rapidly effective cure for the majority of CDI patients so treated. FMT has been used to treat a wide range of other diseases, although conclusions about efficacy in any disease other than CDI must await appropriate well-designed trials. More work needs to be done with FMT, especially to evaluate and ensure its long-term safety. Future studies are likely to narrow the spectrum of organisms that needs to be given to patients to cure CDI, and perhaps other diseases, and to elucidate the mechanisms whereby such therapeutic benefit occurs. FMT is but the first step in this journey.

UR - http://www.scopus.com/inward/record.url?scp=85021868532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021868532&partnerID=8YFLogxK

U2 - 10.1097/PSY.0000000000000511

DO - 10.1097/PSY.0000000000000511

M3 - Article

C2 - 28976455

AN - SCOPUS:85021868532

JO - Psychosomatic Medicine

JF - Psychosomatic Medicine

SN - 0033-3174

ER -